Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency management of stroke (EMS) bridging trial

Stroke

Volumn 30, Issue 12, 1999, Pages 2598-2605

  Lewandowski, Christopher A ^b   Frankel, Michael ^b   Tomsick, Thomas A ^b   Broderick, Joseph ^b   Frey, James ^b   Clark, Wayne ^b   Starkman, Sidney ^b   Grotta, James ^b   Spilker, Judith ^b   Khoury, Jane ^b   Brott, Thomas ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

Acute; Cerebral ischemia; Cerebrovascular disorders; Combination; Drug therapy; Stroke; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECANALIZATION; TREATMENT OUTCOME;

EID: 0032710461     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.12.2598     Document Type: Article

References (15)

1. Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first 6 hours. J Neurol Sci. 1989;91:311-321.
2. Zivin JA, Lyden PD, DeGirolami U, Kochhar A, Mazzarella V, Hemenway CC, Johnston P. Tissue plasminogen activator: reduction of neurologic damage after experimental embolie stroke. Arch Neurol. 1988; 45:387-391.
3. The National Institute of Neurological Disorders, and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
4. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, Marler JR. Urgent therapy for stroke, I: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
5. Zeumer H, Freitag HJ, Knopse V. Intravascular thrombolysis in central nervous system cerebrovascular disease. Neuroimaging Clin N Am. 1992; 2:359-369.
6. Sullivan KL, Gardiner GA Jr, Shapiro MJ, Bonn J, Levin DC. Acceleration of thrombolysis with a high-dose transthrombus bolus technique. Radiology. 1989;173:805-808.
7. Zeumer H, Freitag HJ, Zanella F, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology. 1993;35:159-162.
8. Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke. 1988; 19:802-812.
9. del Zoppo GJ, Ferbert A, Otis S, Bruckmann H, Hacke W, Zyroff J, Harker LA, Zeumer H. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke: a pilot study. Stroke. 1988;19:307-313.
10. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J. Improved reliability of the NIH Stroke Scale using video training: NINDS TPA Stroke Study Group. Stroke. 1994;25:2220-2226.
11. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation. 1987;76: 142-154.
12. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies W. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation. 1996;94:1167-1174.
13. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke: PROACT Investigators: Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29:4-11.
14. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator, the rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol. 1993;14:3-13.
15. Tomsick T, Brott T, Barsan W, Broderick J, Haley EC, Spilker J, Khoury J. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol. 1996;17:79-85.